LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
LEPU BIO-B: Proxy Form for the Annual General Meeting to be held on June 19 2024
LEPU BIO-B: (1) 2023 REPORT OF THE BOARD OF DIRECTORS (2) 2023 REPORT OF THE BOARD OF SUPERVISORS (3) 2023 ANNUAL REPORT (4) 2023 FINANCIAL ACCOUNTS REPORT (5) 2024 FINANCIAL BUDGET (6) 2023 ANNUAL PROFIT DISTRIBUTION PLAN (7) RE-APPOINTMENT OF AUDITOR (8) GENERAL MAN
LEPU BIO-B: NOTICE OF THE 2023 ANNUAL GENERAL MEETING
LEPU BIO-B: Next Day Disclosure Return
LEPU BIO-B: COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE
LEPU BIO-B: VOLUNTARY ANNOUNCEMENT THREE CLINICAL TRIAL RESULTS PRESENTED AT 2024 ASCO ANNUAL MEETING
LEPU BIO-B: Placing of New H Shares under General Mandate
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
LEPU BIO-B: 2023 Annual Report
LEPU BIO-B: VOLUNTARY ANNOUNCEMENT UPDATE ON THE LICENSE AGREEMENT WITH ASTRAZENECA FOR CMG901
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
LEPU BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
LEPU BIO-B: NOTICE OF BOARD MEETING
LEPU BIO-B: VOLUNTARY ANNOUNCEMENT FAST TRACK DESIGNATION GRANTED BY THE FDA TO MRG004A FOR THE TREATMENT OF PANCREATIC CANCER
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
LEPU BIO-B: ARTICLES OF ASSOCIATION
LEPU BIO-B: List of Directors and their Roles and Functions
LEPU BIO-B: (1) POLL RESULTS OF THE 2024 SECOND EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 31, 2024; (2) RE-ELECTION OF DIRECTORS AND SUPERVISORS; (3) CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR; AND (4) AMENDMENTS TO THE ARTICLES OF ASSOCIATION
No Data